Pinned Tweet
$ARWR trades at over $10B today.
If ARO-MAPT's Phase 1 reads positive in 2H 2026, the math says it's worth $55-$90B to a strategic acquirer.
Not a guess. Four independent methodologies. Same range.
Full paper: drive.google.com/file/d/1D5e…
Everybody assumes $ARWR will have to partner ARO-MAPT. That a company that size can’t launch into 7 million patients.
But nobody has to find those patients. They’re already identified, already sitting in a neurologist’s office, and waiting on something better. This would be a two second shot from an autoinjector. Four doses, or less, a year instead of fifty-two, and everything downstream scales with that.
Madrigal launched into MASH with no partner and did $958M in its first full year. They had never sold a drug before.
Vertex was worth $7.7B the day Kalydeco was approved.
On Thursday’s call Chris Anzalone said it is “hard for us to imagine doing a partnership around ARO-MAPT at this point.”
New paper: No Partner Needed
bioboyscout.com/p/no-partner…
$ARWR Take ARO-MAPT alone in the US!
License the rest of the world. Keep the States!
2
47
3,114
$ARWR
- Obesity data by the end of 2026.
- ARO-DIMER-PA in the first half of 2027.
- YOSEMITE HoFH readout in the second half.
- Zodasiran NDA filing by year end.
- New candidates out of the dimer and CNS platforms throughout.
- Initial ARO-MAPT patient data in the second half of 2027.
- Dan Apel said the commercial organization is largely in place, with only incremental additions expected before the sHTG launch, and that it was built to be fully leverageable across plozasiran and then zodasiran.
$ARWR buried the CNS timeline in the back half of today’s call.
James Hamilton: CTAs from two wholly owned CNS candidates around end of 2026 or early 2027, and additional CNS clinical entries by end of 2027.
Chris Anzalone on the ARO-MAPT data: “The opportunity to address CNS targets with an injection under the skin could dramatically expand the diseases we can pursue. I do not think this breakthrough can be overstated.”
Read those together. Tau wasn’t the destination, it was the proof the delivery works. Two more wholly owned CNS programs enter the clinic within months.
The first look at tau in actual Alzheimer’s patients comes in 2027, not 2029.
$ARWR took on $48 million in net debt on Nov 2 to refinance a loan nobody was forcing them to touch.
What they bought was an end to the sweep. Arrowhead no longer has to hand Sixth Street a cut of incoming money.
Meanwhile $300 billion comes off patent for big pharma by 2030. Arrowhead has until 2031 with no amortization.
Whoever has a date loses the negotiation.
New paper covers this in detail: Go Pound Sand
bioboyscout.com/p/go-pound-s…
Something I keep thinking about regarding $ARWR’s CNS competitors. $IONS and $ALNY are both building subq brain delivery while running deep intrathecal pipelines. Nothing forces them to pick. What they could use is a reason to drop intrathecal and focus on subq.
A trial where tau falls beautifully in spinal fluid and the patient barely moves gives management exactly that. The program stays alive, but someone has to explain the gap, and saying “we didn’t reach enough of the brain” is the only answer that doesn’t indict the target. It points at the route instead.
CELIA with diranersen already ran that experiment. Tau down 50-65% in CSF, PET down in every region, dose-response primary missed, and higher doses did no better than 60mg. If more drug doesn’t help, either tau lowering has a ceiling or the drug never got where it needed to go.
Prediction: within 18 months at least one of them quietly drops an intrathecal CNS candidate with no safety reason given. Over a longer horizon I’d expect many more, because neither company ends up carrying a franchise that size on a route they’re actively replacing. No hold, no announcement. It just stops appearing on the pipeline slide while the shuttle work keeps coming up on calls. Watch the slides, not the press releases.
$ARWR sold off today on $IONS guidance and honestly that makes sense. Same population, same launch question, and the sHTG ramp is slower than anybody modeled.
What I can’t get past is the asymmetry. Three weeks ago ARO-MAPT lowered tau 73% in a human brain from a subcutaneous shot under the skin and the stock closed up 0.41%. Today a competitor’s liver launch takes it down double digits.
One of those is a quarter. The other is whether this platform reaches an organ nobody else can get to systemically.
$ARWR — Ionis and Alnylam have built entire CNS franchises on the lumbar puncture. Both are quietly building the subcutaneous version. Neither has to choose yet.
That’s the trap, not the reprieve. A decision you can make tomorrow is a decision you will make tomorrow, and every quarter of delay puts more money into the old road.
Arrowhead went through this in 2016. What it bought took ten years to show up.
New paper’s up: Killing What Works.
$IONS $ALNY
bioboyscout.com/p/killing-wh…
$ARWR showed two weeks ago that a shot under the skin can lower tau in a human brain. New paper is about what that did to everyone else.
$ALNY has five CNS programs, all by lumbar puncture, and confirmed last week they’re building a way around it. $IONS has a neurology franchise on that route and was already working on the alternative. $NVS is running a Phase 3 to 2029 on one road while paying for the other.
bioboyscout.com/p/nobody-get…
$ARWR showed on Oct 14 that a shot under the skin can lower tau in a human brain. New paper is about why nobody else has.
$ALNY was asked about brain shuttles this morning. They're building several, but no disclosed data, and no timeline.
$NVS is running a tau drug into the spinal canal while holding a license to the subQ alternative. $DNLI crossed with an enzyme and is now trying an ASO, by IV.
Convenience is an argument about who takes a medicine, not whether it works.
bioboyscout.com/p/nobody-els…
A regional evidence map for tau and $ARWR. Where the pathology sits in Alzheimer's, PSP, CBD and MAPT-FTD, against what each delivery route has been shown to reach.
Intrathecal siRNA in monkey: 86% knockdown in thoracic cord, 23% in putamen, none at all in caudate. SubQ reached all twelve regions with no gradient by depth.
ARO-SNCA hit >90% in substantia nigra. ARO-MAPT was never profiled there.
🤖 Made with AI
In June I published four papers on why Novartis, Lilly or Roche might be pushed into buying $ARWR. Those papers named two events: a gate the thesis had to survive, and a first bid that starts the cascade.
The gate opened on Oct 14. Nobody has played the check.
New note grades my own work.
Odds through 2027: 50% independent. Roche, Lilly, Novartis 15% each. $RHHBY $LLY $NVS
bioboyscout.com/p/check-has-…
$ARWR reported the first gene silencing in a human brain from a shot under the skin. The stock closed up 24 cents.
Wave got +74% on two patients. Intellia +55% on six. Sarepta +35% in March on two programs licensed from Arrowhead.
Same category of data. Same market. The hardest organ got four tenths of one percent.
UBS says it plainly: ARO-MAPT is "not included in our valuation."
A blank field is not an estimate of zero. It is a decision not to estimate.
bioboyscout.com/p/the-liver-…
$ARWR silenced a gene in the human brain with a shot under the skin. Mean 73% tau reduction, 85% in one person.
My reaction note is up.
The headline is 73%. The number that matters is 105, the study day. Last dose was Day 15, so that was measured ninety days after the drug stopped.
A primate comparison Arrowhead published in May that nobody has connected to today: spinal canal delivery varied 22x across brain regions. Under the skin, under 4x.
The Bishop Moved
bioboyscout.com/p/the-bishop…
WOW! 73%!!!
$ARWR just silenced a gene in the human brain with a shot under the skin. Nobody has ever done that. Not once. Not anywhere.
Here's the number nobody's reading: Day 105 is ninety days after the last dose. That's not a peak. That's a floor that held for three months with no drug on board.
Biogen gets 50-65% through a needle in the spine.
Arrowhead got 73% through a needle in the arm.
Two doses. Not three.
PSP and FTD regulatory talks already underway.
The brain had no book. Arrowhead just wrote the first page.
Today we announced interim Phase 1/2a clinical data for ARO-MAPT.
The results represent an important step in clinical validation of our TRiM platform for delivering siRNA to the central nervous system.
Join today’s webinar to learn more: bit.ly/3VMXyCD
$ARWR nobody takes intrathecal injections for twenty years before symptoms start. Presymptomatic tau lowering requires a subcutaneous drug. That is what gets tested tomorrow.
$ARWR don't want to sound hyperbolic, but tomorrow could be one of the most important datapoints in drug development of the decade (on par with Glp1):
Can subQ-delivered RNAi substantially knock down genes in the CNS? And can we see the data of the first drug to make a real dent against Alzheimer's (safe and due to subQ could be dosed presymptomatically)?
52
3,182
Roche licensed an ALK7 RNAi obesity drug from Rona today. Up to $100M near-term, $1.06B in milestones behind it. That makes five companies on ALK7: $ARWR, $ALNY, GSK, Novo, Roche. Nobody spends that way on a target they think is wrong.
Arrowhead is the only one to have reported human data, silencing the gene in human fat cells in January. Not mice. Not monkeys. People.
Here's what I'd actually watch.
The target isn't the hard part. ALK7 is published. The human genetics are published. Anyone can look up which gene to silence.
The hard part is getting an siRNA into a fat cell and keeping it there. That's chemistry, delivery, and a decade of failures nobody writes papers about. It's where these programs die.
A hundred million near-term against $1.16B total isn't conviction. It's an option. Roche bought a call option on a program that still has to clear every step Arrowhead already cleared.
Roche never disclosed the stage, but Rona's pipeline shows preclinical. That's two to three years to first human data, if nothing breaks.
Roche just paid a hundred million dollars to start where Arrowhead already finished. That's the going rate for a seat at a table somebody else set.
Wednesday, $ARWR reports its tau number. A 60 gets called a triumph, a 45 a disaster, inside an hour.
Two tau drugs already proved that reading wrong. One removed 98% of its target and changed nothing. The other cleared tangles from living brains and still missed its endpoint, with the best result at the lowest dose.
The number answers one question: can a shot under the skin reach the brain. Not whether lowering tau helps anyone.
What to watch instead.
New paper: Ninety-Eight Percent of Nothing
bioboyscout.com/p/ninety-eig…
The FDA built a fast lane for drug reviews four years ago.
First three years: six requests, zero accepted.
This week $ARWR walked in.
Why was the lane empty? To use it you hand the FDA your whole application minus the final study reports, months early. Most filings are a scramble that ends the night before.
You cannot buy an increment. You pay for it in advance, with work nobody watches.
New note: The Increment
bioboyscout.com/p/the-increm…
On October 14, $ARWR tests whether a shot under the skin can reach the human brain.
The key: an antibody fragment that rides the transferrin receptor across the blood-brain barrier.
The lock: two patents granted this year.
Most investors have never looked at either.
The Fab Choice
bioboyscout.com/p/the-fab-ch…



